dendritic cell-myeloma fusion vaccine

The dendritic cell-myeloma fusion vaccine is an autologous, personalized cancer vaccine generated by chemically fusing a patient's dendritic cells with their own myeloma cells. This fusion creates hybrid cells capable of presenting a broad array of myeloma-associated antigens in the context of dendritic cell-mediated costimulation, thus activating and expanding tumor-specific T cell and humoral immune responses. The vaccine is typically administered with adjunctive agents such as GM-CSF for immunostimulation, and has been evaluated both as a stand-alone immunotherapy and in combination with autologous stem cell transplantation and other standard-of-care therapies in multiple myeloma. The primary indication studied is multiple myeloma, especially in the post-transplant or relapsed/refractory settings. Clinical trials, including randomized phase II studies, have demonstrated robust immunologic responses and disease stabilization in treated patients, though a significant survival advantage over standard maintenance has not been statistically confirmed to date[2][3][4][5][7]. The vaccine remains investigational, with production individualized to each patient in specialized cell processing facilities.

Other names

DC-MM fusion vaccineDC/myeloma fusion vaccinedendritic cell-tumor fusion vaccineDC/MM fusion vaccineDC-myeloma vaccine